Bone Morphogenetic Proteins Market Statistics
Bone morphogenetic proteins (BMP) have been a continuous part of medical research and development for the past couple of decades. While initial experiments underscored the osteogenic potential of BMPs, recent studies have revealed their involvement in various cell regulatory processes. Such themes have boded well for the global bone morphogenetic protein market size, which will balloon around 1.2X during 2021-2027. In addition, the market will echo a moderate 2.9% CAGR throughout the predefined time-frame.
Rising caseloads of sports-associated injuries and increasing inclination toward minimally-invasive surgeries are pushing BMP demand. Consequently, market players are collaborating with medical researchers to develop innovative BMPs that will serve other healthcare purposes, including cerebrovascular diseases and ocular conditions.
However, bone morphogenetic proteins market is witnessing critical hurdles in the form of product recalls due to reported adversaries, off-label usage, and restricted approval from the governmental agencies.
Upsurge in Sports-related Injuries to Spur BMP Production
The US alone witnesses over 3.5 million sports-related injuries every year, with about a third occurring athletic fields or sports facilities. (Source- Carryortho.com)
Such alarming numbers have influenced market players to scale up development of bone morphogenetic protein supplements. Bone morphogenetic proteins induce bone and cartilage formation and play instrumental role in multiple non-osteogenic processes. Given their osteogenic properties, bone morphogenetic proteins find use in several areas of medicine, including orthopedics and dentistry, as well as in sport and rehabilitation.
Therefore, rise in sports-associated injuries will offer conducive grounds for players in the global bone morphogenetic proteins market over the forecast period.
Demand to Further Climb Citing Age-related Bone Disorders
Osteoarthritis (OA) is the most frequent form of arthritis, with geriatric population more vulnerable to the disorder. That said, OA symptoms generally begin surfacing after age of 40 years, and worsen over time. Due to such age-related bone conditions, cartilages within the joints disintegrate, triggering stiffness and pain.
Empirical evidence suggests that bone morphogenetic proteins are critical in protecting against cartilage damage due to trauma or inflammation. These naturally occurring proteins amalgamate with various receptor combinations and, thus, activate different intracellular signaling pathways. Reduced functioning of BMP-associated receptors hampers intrinsic repair capability of affected cartilage. As such, multifunctional impacts of bone morphogenetic proteins have garnered huge attention from stakeholders and researchers alike for cartilage damage treatment in people suffering from degenerative diseases.
Hence, increasing frequency of age-related bone disorders, coupled with strong geriatric footprint, is triggering BMP demand.
| Data Points | Market Insights |
| Market Value 2021 | US$ 593.35Million |
| Market Value 2027 | US$ 704.37 Million |
| Market Growth Rate 2019-2027 | 2.9% |
| Top Regional Market | North America |
| Key Players | Cellumed Co. Ltd, Sigma-Aldrich Corporation, R&D Systems ProSpec, DePuy Synthes, Ember Therapeutics Inc |
| Segment | Product type (rhBMP 2 rhBMP 7) Application (Spinal fusion, Trauma, Reconstructive, Oral maxillofacial surgery, Others) |
rhBMP-2 Continues to Fetch Greater Revenues
Recombinant BMP-7 (rhBMP-7) and recombinant BMP-2 (rhBMP-2) are the bone morphogenetic proteins that have received approval by the US FDA for therapeutic usage, given their at-length osteoinductive properties.
Among these BMPs, rhBMP-2 holds significant chunk of bone morphogenetic proteins market. High acceptance of the protein category among physicians and surgeons, in tandem with rising caseloads of sports injuries, are responsible for its wider usage.
rhBMP-2 (INFUSE by Medtronic) received approval by the US FDA in 2002 for restricted usage in single-level anterior lumbar interbody fusion (ALIF) surgery. In 2004, FDA loosened their stringency to extend rhBMP-2 application in treating acute open tibial fractures. Furthermore, the government agency endorsed rhBMP-2 use as substitute to autogenous bone grafting for localized alveolar ridge augmentation.
Despite cost and risk profile, rhBMP-2 remains a preferred bone morphogenetic protein in numerous anatomical locations for FDA-approved and off-label use cases. The market study further reveals that rhBMP-2 will overshadow rhBMP-7 through the coming decade.
BMP Application in Spinal Fusion Stays Prominent
Spinal fusion remains the target application category for bone morphogenetic protein producers. Studies have highlighted importance of bone morphogenetic proteins in stimulating spinal fusion surgery faster compared to that of conventional bone graft surgery. As such, bone morphogenetic proteins offer surgeons liberty to perform the procedure, leading to better fusion rate and avoiding risks pertaining to iliac crest autograft (hip) graft harvest.
Avoiding hip graft cuts down surgery duration and decreases complication rates, ensuring faster and less painful recovery. With growing spinal surgery incidences and ease of surgery with bone morphogenetic proteins, healthcare institutes are increasingly turning to BMPs in performing spinal fusion.
Besides, favorable reimbursement norms for spine infusion procedures and increasing inclination toward minimally-invasive procedures will boost deployment of bone morphogenetic proteins in spinal fusion.
Apart from that, medical think thanks globally are doing comprehensive research to uncover therapeutic potential of bone morphogenetic proteins, for instance in joint replacement surgery and dentistry.
Regional Analysis: North America to Maintain its Market Hegemony
Citing well-established healthcare infrastructure and technology maturity in medical science, North America continues to capture driver’s seat in global bone morphogenetic proteins market.
Surveys reveal that around 296,000 Americans are enduring a spinal cord injury (SCI).
Moreover, the developed country witnesses 17,810 new incidents of spinal cord injuries every year.
These trends have supported the adoption of INFUSE bone morphogenetic proteins in North America. To encourage at-scale bone morphogenetic proteins deployment in various treatments, regional agencies, including the US FDA, have gradually increased BMP approval rate. Coupled with considerable healthcare investments, this has enabled academic and research institutes to explore possible use cases of bone morphogenetic proteins.
In a similar fashion, the bone morphogenetic proteins market in Europe is making significant strides and follows North America in terms of value share.
European Union (EU) is home to over 200,000 patients living with a spinal cord injury, with 10, 000 new incidents adding to the caseloads every year.
Competitive Landscape
The global bone morphogenetic proteins market is moderately competitive, with small number of incumbents grabbing major slice of overall revenue. These established players are ramping up their R&D funding for clinical research of bone morphogenetic proteins and inorganic strategies such as mergers and acquisitions (M&A).
That being considered, with tech advancements and product innovation, small to mid-size enterprises (SME) are strengthening their market foothold by launching new products at competitive price points.
Critical developments include:
- StemGen has developed hrBMP4, a protein of TGF-Beta Superfamily, which attaches to specific receptors in patients suffering from Glioblastoma multiforme (GBM).
- Medtronic has received US FDA approval of a clinical trial for injection of its proprietary Infuse™ Bone Graft in transforaminal lumbar interbody fusion (TLIF) spine procedures.
- Ember Therapeutics is focused on clinical usage of BMP-7 for disease modification (cartilage building) in OA.
Some of the prominent market player include –
- Cellumed Co. Ltd
- Sigma-Aldrich Corporation
- R&D Systems
- ProSpec
- DePuy Synthes
- Ember Therapeutics Inc
Type Outlook (Revenue, USD Million)
- rhBMP 2
- rhBMP 7
Application Outlook (Revenue, USD Million)
- Spinal fusion
- Trauma
- Reconstructive
- Oral maxillofacial surgery
- Others
Frequently Asked Questions
Which region will hold a largest share in Global Bone Morphogenetic Protein Market?
North America is anticipated to hold the highest share in 2021.
What will be the growth rate of Global Bone Morphogenetic Protein Market?
The Global Bone Morphogenetic Protein Market will exhibit growth at a CAGR of 2.90% during forecasting period 2022-2027.
What is scope of the Global Bone Morphogenetic Protein market report?
Global Bone Morphogenetic Protein Market report include all PESTEL, PORTER, Recommendations for Investors & Leaders, COVID-19 Impact analysis, and market estimation of the forecast period.
List the key players in Global Bone Morphogenetic Protein market?
The prominent key players in the Global Bone Morphogenetic Protein Market are – ProSpec, Ember Therapeutics, R&D Systems, Thermo Fisher Scientific, Inc., DePuy Synthes, Nuvasive, Inc., Orthofix Holdings, Inc., Smith and Nephew, Medtronic, Cellumed Co. Ltd., Stryker, and,Sigma Aldrich Co.
What is the study period of this market?
The Global Bone Morphogenetic Protein Market is forecasted from 2021 to 2027.
Table Of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast 2022-2032, By Type Outlook
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Type Outlook, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Type Outlook, 2022-2032
5.3.1. rhBMP 2
5.3.2. rhBMP 7
5.4. Y-o-Y Growth Trend Analysis By Type Outlook, 2017-2021
5.5. Absolute $ Opportunity Analysis By Type Outlook, 2022-2032
6. Global Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast 2022-2032, By Application Outlook
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Application Outlook, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Application Outlook, 2022-2032
6.3.1. Spinal fusion
6.3.2. Trauma
6.3.3. Reconstructive
6.3.4. Oral maxillofacial surgery
6.3.5. Others
6.4. Y-o-Y Growth Trend Analysis By Application Outlook, 2017-2021
6.5. Absolute $ Opportunity Analysis By Application Outlook, 2022-2032
7. Global Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Type Outlook
8.2.3. By Application Outlook
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type Outlook
8.3.3. By Application Outlook
8.4. Key Takeaways
9. Latin America Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Argentina
9.2.1.4. Chile
9.2.1.5. Peru
9.2.1.6. Rest of Latin America
9.2.2. By Type Outlook
9.2.3. By Application Outlook
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type Outlook
9.3.3. By Application Outlook
9.4. Key Takeaways
10. Europe Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. Italy
10.2.1.3. France
10.2.1.4. U.K.
10.2.1.5. Spain
10.2.1.6. Russia
10.2.1.7. BENELUX
10.2.1.8. Rest of Europe
10.2.2. By Type Outlook
10.2.3. By Application Outlook
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type Outlook
10.3.3. By Application Outlook
10.4. Key Takeaways
11. East Asia Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By Type Outlook
11.2.3. By Application Outlook
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type Outlook
11.3.3. By Application Outlook
11.4. Key Takeaways
12. South Asia Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Malaysia
12.2.1.4. Indonesia
12.2.1.5. Rest of South Asia
12.2.2. By Type Outlook
12.2.3. By Application Outlook
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type Outlook
12.3.3. By Application Outlook
12.4. Key Takeaways
13. Oceania Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Type Outlook
13.2.3. By Application Outlook
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type Outlook
13.3.3. By Application Outlook
13.4. Key Takeaways
14. MEA Bone Morphogenetic Proteins Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC
14.2.1.2. Rest of MEA
14.2.2. By Type Outlook
14.2.3. By Application Outlook
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type Outlook
14.3.3. By Application Outlook
14.4. Key Takeaways
15. Key Countries Bone Morphogenetic Proteins Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Type Outlook
15.1.2.2. By Application Outlook
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Type Outlook
15.2.2.2. By Application Outlook
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Type Outlook
15.3.2.2. By Application Outlook
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Type Outlook
15.4.2.2. By Application Outlook
15.5. Argentina
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Type Outlook
15.5.2.2. By Application Outlook
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Type Outlook
16.3.3. By Application Outlook
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Cellumed Co. Ltd
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Sigma-Aldrich Corporation
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. R&D Systems
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. ProSpec
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. DePuy Synthes
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Ember Therapeutics Inc
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Request Free Sample
